McDonough Capital Management Inc bought a new position in Pfizer Inc. (NYSE: PFE – Get Rating) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 9,290 shares of the biopharmaceutical company stock, valued at approximately $ 549,000. Pfizer comprises about 0.4% of McDonough Capital Management Inc’s investment portfolio, making the stock its 28th largest position.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. State Street Corp grew its position in Pfizer by 1.8% in the 4th quarter. State Street Corp now owns 284,816,832 shares of the biopharmaceutical company stock worth $ 16,818,434,000 after purchasing an additional 5,013,651 shares during the last quarter. Geode Capital Management LLC grew its position in Pfizer by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 101,065,073 shares of the biopharmaceutical company stock worth $ 5,952,333,000 after purchasing an additional 1,471,980 shares during the last quarter. Morgan Stanley lifted its stake in shares of Pfizer by 3.4% in the 2nd quarter. Morgan Stanley now owns 47,894,080 shares of the biopharmaceutical company stock worth $ 1,875,532,000 after acquiring an additional 1,582,052 shares during the period. Nuveen Asset Management LLC lifted its stake in shares of Pfizer by 18.0% in the 4th quarter. Nuveen Asset Management LLC now owns 28,086,667 shares of the biopharmaceutical company stock worth $ 1,658,518,000 after acquiring an additional 4,278,167 shares during the period. Finally, UBS Asset Management Americas Inc. lifted its stake in shares of Pfizer by 2.0% in the 3rd quarter. UBS Asset Management Americas Inc. now owns 23,728,801 shares of the biopharmaceutical company stock worth $ 1,020,576,000 after acquiring an additional 457,513 shares during the period. Hedge funds and other institutional investors own 66.50% of the company stock.
Pfizer stock opened at $ 48.51 on Thursday. The firm has a market cap of $ 272.18 billion, a PE ratio of 11.13, a P / E / G ratio of 0.61 and a beta of 0.76. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. The firm’s 50 day moving average price is $ 51.22 and its two-hundred day moving average price is $ 52.43. Pfizer Inc. has a twelve month low of $ 38.70 and a twelve month high of $ 61.71.
Pfizer (NYSE: PFE – Get Rating) last released its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $ 1.62 earnings per share for the quarter, missing the estimate consensus of $ 1.66 by ($ 0.04). The company had revenue of $ 25.66 billion during the quarter, compared to analyst estimates of $ 24.73 billion. Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The firm’s quarterly revenue was up 76.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $ 0.93 EPS. Equities analysts anticipate that Pfizer Inc. will post 6.62 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 10th. Shareholders of record on Friday, May 13th were paid a $ 0.40 dividend. The ex-dividend date was Thursday, May 12th. This represents a $ 1.60 annualized dividend and a yield of 3.30%. Pfizer’s dividend payout ratio is presently 36.70%.
A number of brokerages have recently weighed in on PFE. JPMorgan Chase & Co. set a $ 57.00 price target on shares of Pfizer in a research note on Tuesday, May 3rd. Berenberg Bank set a $ 50.00 target price on shares of Pfizer in a research note on Friday, May 27th. SVB Leerink began coverage on shares of Pfizer in a research note on Monday, May 23rd. They set a “market perform” rating and a $ 55.00 target price for the company. Citigroup increased their target price on shares of Pfizer from $ 46.00 to $ 57.00 and gave the company a “neutral” rating in a research note on Tuesday, April 5th. Finally, StockNews.com raised shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. Ten investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Buy” and an average price target of $ 57.26.
In other news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $ 50.00, for a total transaction of $ 1,645,400.00. Following the transaction, the executive vice president now owns 38,146 shares in the company, valued at approximately $ 1,907,300. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction on Monday, May 16th. The stock was sold at an average price of $ 50.50, for a total transaction of $ 202,000.00. Following the transaction, the senior vice president now owns 15,064 shares in the company, valued at approximately $ 760,732. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,126 shares of company stock worth $ 2,075,003. 0.05% of the stock is currently owned by company insiders.
Pfizer Profile: (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Receive News & Ratings for Pfizer Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.